Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Amortization of Deferred Charges (2022 - 2025)

Historic Amortization of Deferred Charges for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $441000.0.

  • BioXcel Therapeutics' Amortization of Deferred Charges rose 31603.77% to $441000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.2 million, marking a year-over-year increase of 19995.18%. This contributed to the annual value of $6.5 million for FY2024, which is 24951.92% up from last year.
  • Per BioXcel Therapeutics' latest filing, its Amortization of Deferred Charges stood at $441000.0 for Q3 2025, which was up 31603.77% from $393000.0 recorded in Q2 2025.
  • In the past 5 years, BioXcel Therapeutics' Amortization of Deferred Charges ranged from a high of $2.7 million in Q4 2024 and a low of $96000.0 during Q2 2024
  • In the last 4 years, BioXcel Therapeutics' Amortization of Deferred Charges had a median value of $385000.0 in 2023 and averaged $735000.0.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first plummeted by 7303.37% in 2024, then skyrocketed by 31603.77% in 2025.
  • BioXcel Therapeutics' Amortization of Deferred Charges (Quarter) stood at $322000.0 in 2022, then soared by 104.04% to $657000.0 in 2023, then soared by 314.31% to $2.7 million in 2024, then tumbled by 83.8% to $441000.0 in 2025.
  • Its Amortization of Deferred Charges stands at $441000.0 for Q3 2025, versus $393000.0 for Q2 2025 and $2.7 million for Q1 2025.